Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration
Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration, from the December 2008 issue of Clinical Therapeutics.
Please click here to read the abstract.